By Karima Yadi, MSc and Lionel Maritan, MSc, BD Medical – Pharmaceutical Systems
Previously published in Drug Development & Delivery – www.drug-dev.com
Biologics now constitute a significant element of available medical treatments. Owing to their clinical and commercial success, biologics are a rapidly growing class and have become a dominant therapeutic modality.1 This, and the increased demand for home healthcare, driven by the ever-increasing prevalence of chronic diseases, is fueling increased demand for self-injection devices.2
For manufacturers, while many are turning their attention to devices that support injection of higher volumes and greater viscosities, there remains a need to further innovate in the 1-mL space and provide innovative injection solutions for viscous drugs in the 2-mL space to improve delivery outcomes, patient quality of life, and adherence to treatment.
Reducing injection frequency is one of the strategies implemented by pharmaceutical companies. To reach this objective, they will be looking to increase their drug dosage and potency, either by increasing the drug concentration and/or delivery of larger volumes.3,4 Needle innovations, including the usage of shorter needles with ultra-thin wall technology for prefilled syringes, supports the delivery of drugs with greater volumes and viscosities, which greatly enhances end-user experience.